Prostate Cancer Market Research Reports

Prostate Cancer Market Research

The research reports provide a detailed analysis of the most updated technology trends and developments in the global Prostate C... view more

Sort By :

TITLE Price Buy Now More options

Prostate Cancer – Pipeline Review, H1 2013 Prostate Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, ''Prostate Cancer - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic develop	$ 2500
Metastatic Prostate Cancer – Pipeline Review, H1 2013 Metastatic Prostate Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, ''Metastatic Prostate Cancer - Pipeline Review, H1 2013'', provides an overview of the indication’s therapeutic pipeline. This report provides information on t	$ 2000
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline Review, H1 2013 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, ''Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer -	$ 2000
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets REPORT HIGHLIGHTSThis report provide:An overview of the market for the prevention and treatment of prostate cancer, with coverage of the mechanisms of disease development, detection and diagnosis, and anticancer...	$ 5450
PharmaPoint: Prostate Cancer - Current and Future Players PharmaPoint: Prostate Cancer - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Prostate Cancer - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analy	$ 2995
PharmaPoint: Prostate Cancer - United States Drug Forecast and Market Analysis to 2022 PharmaPoint: Prostate Cancer - United States Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Prostate Cancer - United States Drug Forecast and Market Analysis to 2022”. The recent	$ 4995
Prostate Cancer Global Clinical Trials Review, H2, 2012 Prostate Cancer Global Clinical Trials Review, H2, 2012 Summary GlobalData''s clinical trial report, “Prostate Cancer Global Clinical Trials Review, H2, 2012" provides data on the Prostate Cancer clinical trial scenario. This report provides ele	$ 2500
PharmaPoint: Prostate Cancer - United Kingdom Drug Forecast and Market Analysis to 2022 PharmaPoint: Prostate Cancer - United Kingdom Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Prostate Cancer - United Kingdom Drug Forecast and Market Analysis to 2022”. The recen	$ 4995
PharmaPoint: Prostate Cancer - France Drug Forecast and Market Analysis to 2022 PharmaPoint: Prostate Cancer - France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Prostate Cancer - France Drug Forecast and Market Analysis to 2022”. The recent approvals of s	$ 4995
PharmaPoint: Prostate Cancer - Germany Drug Forecast and Market Analysis to 2022 PharmaPoint: Prostate Cancer - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Prostate Cancer - Germany Drug Forecast and Market Analysis to 2022”. The recent approvals of	$ 4995
PharmaPoint: Prostate Cancer - Italy Drug Forecast and Market Analysis to 2022 PharmaPoint: Prostate Cancer - Italy Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Prostate Cancer - Italy Drug Forecast and Market Analysis to 2022”. The recent approvals of sec	$ 4995
PharmaPoint: Prostate Cancer - Spain Drug Forecast and Market Analysis to 2022 PharmaPoint: Prostate Cancer - Spain Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Prostate Cancer - Spain Drug Forecast and Market Analysis to 2022”. The recent approvals of sec	$ 4995
PharmaPoint: Prostate Cancer - Japan Drug Forecast and Market Analysis to 2022 PharmaPoint: Prostate Cancer - Japan Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Prostate Cancer - Japan Drug Forecast and Market Analysis to 2022”. The recent approvals of sec	$ 4995
PharmaPoint: Prostate Cancer - Australia Drug Forecast and Market Analysis to 2022 PharmaPoint: Prostate Cancer - Australia Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Prostate Cancer - Australia Drug Forecast and Market Analysis to 2022”. The recent approval	$ 4995
PharmaPoint: Prostate Cancer - Canada Drug Forecast and Market Analysis to 2022 PharmaPoint: Prostate Cancer - Canada Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Prostate Cancer - Canada Drug Forecast and Market Analysis to 2022”. The recent approvals of s	$ 4995
Zoladex (Prostate Cancer) - Forecast and Market Analysis to 2022 Zoladex (Prostate Cancer) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Zoladex (Prostate Cancer) - Forecast and Market Analysis to 2022”. The recent approvals of second-line	$ 3495
Lupron Depot (Prostate Cancer) - Forecast and Market Analysis to 2022 Lupron Depot (Prostate Cancer) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Lupron Depot (Prostate Cancer) - Forecast and Market Analysis to 2022”. The recent approvals of s	$ 3495
Eligard (Prostate Cancer) - Forecast and Market Analysis to 2022 Eligard (Prostate Cancer) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Eligard (Prostate Cancer) - Forecast and Market Analysis to 2022”. The recent approvals of second-line	$ 3495
Trelstar (Prostate Cancer) - Forecast and Market Analysis to 2022 Trelstar (Prostate Cancer) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Trelstar (Prostate Cancer) - Forecast and Market Analysis to 2022”. The recent approvals of second-li	$ 3495
Firmagon (Prostate Cancer) - Forecast and Market Analysis to 2022 Firmagon (Prostate Cancer) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Firmagon (Prostate Cancer) - Forecast and Market Analysis to 2022”. The recent approvals of second-li	$ 3495

First

Last

Live Chat Support

Connect With Us

Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Use our subscription option and keep yourself updated about the latest industry analysis reports. We have research reports for over 5000 micro markets; you can access and utilize them at economical budgets.

More about our Subscription option

Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: